We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CHANCES IPH5301
Previous Study | Return to List | Next Study

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05143970
Recruitment Status : Recruiting
First Posted : December 3, 2021
Last Update Posted : February 24, 2022
Innate Pharma
Information provided by (Responsible Party):
Institut Paoli-Calmettes

Brief Summary:

CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer.

The trial will be conducted in two parts, Part I- Dose escalation: This part aims to identify the maximum tolerated dose (MTD) of IPH5301 agent in monotherapy and recommended phase 2 dose (RP2D) for future trials, followed by a safety expansion study part cohort.

Part II- Expansion cohort: A total of 12 HER2+ cancer patients, respectively 6 breast cancer patients and 6 gastric cancer patients, is planned to be enrolled into the next expansion cohort to select a recommended dose of IPH5301 to be administered in combination with chemotherapy and trastuzumab for evaluation in future trials with selected advanced solid tumors.

Condition or disease Intervention/treatment Phase
Metastatic Cancer Metastatic Breast Cancer Metastatic Pancreatic Cancer Metastatic Gastric Cancer Metastatic Lung Cancer Metastatic Ovary Cancer Oesophageal Cancer Endometrial Cancer Advanced Solid Tumor Drug: IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 27 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Actual Study Start Date : January 26, 2022
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2024

Arm Intervention/treatment
Experimental: IPH5301 administration

Part I- Dose escalation:

Escalating dose levels of IPH5301 will be evaluated.

Part II-Cohort Expansion:

IPH5301 will be administrated in combination with trastuzumab and paclitaxel


Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months.

Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD).

Primary Outcome Measures :
  1. Occurrence of dose limiting toxicity (DLT) of IPH5301 in monotherapy in the dose escalation and in combination with paclitaxel and trastuzumab in the expansion cohort [ Time Frame: 1 month ]
    DLTs would include any grade 3 toxicity or higher that occurs during the first 4 weeks from the first injection of IPH5301, with the some exceptions

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Patients with incurable advanced and/or metastatic cancer.
  • Patients with any of the following cancers:

    1. In dose escalation: carcinoma of the breast, stomach, esophagus, pancreas, endometrium, ovary or lung.
    2. In cohort expansion (HER2-positive): carcinoma of the breast and gastric/gastro-esophageal that express HER2 (2 cohorts) . Eligibility is based on HER2 overexpression as determined locally.
  • Prior treatment with at least one prior systemic therapy in the advanced metastatic setting

    1. Dose escalation: no limit on number of prior systemic therapies and considered as failing standard therapeutic alternatives and candidate to a phase I study by a multi-disciplinary tumor board.
    2. Cohort expansion: patients must have previously re-ceived (or be considered as non-eligible to) all authorized standard treatments
  • Breast cancer: patient must have received prior (or be considered as ineligible to) trastuzumab pertuzumab, trastuzumab emtansine, trastuzumab deruxtecan and capecitabine+anti-HER2 (trastuzumab, lapatinib or trastuzumab tucatinib) according to label.
  • Gastric cancer: patient must have received (or be con-sidered as ineligible to) prior treatment with platinum salts and trastuzumab.
  • Presence of at least one measurable lesion by RECIST outside of the CNS.
  • At least 18 years of age.
  • ECOG performance status of ≤1.
  • For patients included in cohort expansion, adequate echocar-diogram, with a left ventricular ejection fraction ≥55%. Patients with a history of LVEF decline (< 50%) on anti-HER2 treatment will not be allowed to participate.
  • For patients included in the cohort expansion, feasibility of obtaining tumor biopsy at study entry.
  • All non-hematological AEs related to prior therapy must have completely resolved or improved to Grade 1 prior to screening for this study (except for alopecia).

Exclusion Criteria:

  • Prior treatment with other monoclonal antibodies or small mol-ecules targeting CD73 or the adenosine pathway.
  • Patients with known spinal cord compression.
  • Patients with grade 2 or higher peripheral neuropathy.
  • Symptomatic, untreated, or actively progressing central nerv-ous system (CNS) metastases. Patients with suspected CNS involvement at screening should have an magnetic resonance imaging (MRI) (preferred) or computed tomography (CT) each preferably with IV contrast of the brain prior to study entry to rule them out. Asymptomatic patients with treated CNS lesions are eligible, provided that definied criteria are met
  • Known allergic reactions attributed to compounds of similar product.
  • Patients with dyspnea at rest and history of pneumonit-is/interstitial lung disease.
  • Patients with any serious underlying medical condition that would impair the subject from receiving or tolerating the planned treatment.
  • Concurrent enrollment in another clinical trial, unless it is an non-interventional clinical study or the follow-up period of an interventional study.
  • Any concurrent treatment with any anti-cancer agents or drugs that could have anti-tumor effects.
  • Active auto-immune disease within the past 2 years.
  • ≥ Grade 3 immune related AE or an immune-related neuro-logic or ocular AE of any grade while receiving prior immunotherapy.
  • Subjects who have undergone major surgery <28 days prior to starting study drug.
  • Treatment with any conventional or investigational anticancer therapy within 28 days prior to day 1 of study treatment.
  • Receipt of live attenuated vaccine or SARS-CoV-2 vaccine within 30 days prior to the first dose of study drug
  • Primary immunodeficiency and/or history of allogenic transplantation.
  • Current uncontrolled infection.
  • Hepatitis B, C or HIV-positive patients.
  • Subjects with a history of other active invasive malignancies during the past three years with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%) and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer).
  • Pregnant or breastfeeding women.
  • Participants with abnormal coagulation profiles or any history of coagulopathy within the 6 months prior to the first dose of IMP, as well as history of deep vein thrombosis, pulmonary embolism, cerebrovascular accident or other arterial thrombus. Participants being treated with an anticoagulant (eg, warfarin or heparin) for a thrombotic event that occurred more than 6 months before en-rollment, or for an otherwise stable and allowed medical condition (eg, well-controlled atrial fibrillation), provided that dose and co-agulation parameters (as defined by local standard of care) are stable for at least 1 month prior to the first dose of IMP are allowed.
  • Subjects with dementia or altered mental status that would preclude understanding and rendering of informed consent document.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05143970

Layout table for location contacts
Contact: DOMINIQUE GENRE 0491223778 drci.up@ipc.unicancer.fr

Layout table for location information
Institut Paoli Calmettes Recruiting
Marseille, France
Contact: Anthony Gonçalves, MD PhD       goncalves@ipc.unicancer.fr   
Sponsors and Collaborators
Institut Paoli-Calmettes
Innate Pharma
Layout table for investigator information
Principal Investigator: Anthony GONCALVES, MD PhD Institut Paoli-Calmettes
Layout table for additonal information
Responsible Party: Institut Paoli-Calmettes
ClinicalTrials.gov Identifier: NCT05143970    
Other Study ID Numbers: CHANCES-IPC 2021-008
First Posted: December 3, 2021    Key Record Dates
Last Update Posted: February 24, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Ovarian Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Endocrine System Diseases
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Diseases
Ovarian Diseases
Adnexal Diseases
Gonadal Disorders
Antineoplastic Agents, Immunological
Antineoplastic Agents